Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProvexis Regulatory News (PXS)

Share Price Information for Provexis (PXS)

Share Price is delayed by 15 minutes
Get Live Data
1.25    0.125 (11.11%)
Bid:
1.20
Ask:
1.25
Spread: 0.05 (4.167%)
Market Cap: £29.32m
PXS Live PriceLast checked at - London Stock Exchange

Intraday Provexis Share Chart

Product Launch

16 Dec 2005 07:00

Provexis PLC16 December 2005 PROVEXIS PLC ("Provexis" or the "Company") UK Launch of Sirco(TM) Provexis, the nutraceutical company that develops scientifically-provenfunctional and medical foods, is delighted to confirm the launch of itsSirco(TM) heart health juice drink in the UK in January 2006. The Company has so far secured an initial distribution base with two of the fivelargest supermarket retailers in the UK, which for reasons of commercialconfidentiality cannot be named at present. Both retailers will distributeSirco(TM) nationally. Within the larger of the two supermarket groups, Sirco(TM)will be initially available in premier stores which represent, by weighteddistribution, approximately 35 per cent. of their total UK distribution base.Within the second supermarket chain, Sirco(TM) will be initially available, byweighted distribution, across 70 per cent. of their total UK distribution base.Both retailers will stock Sirco(TM) in one litre packs of both flavour variants,Apple & Blueberry and Orange, and the drink will be located in the chilled fruitjuice section. The Company is in on-going discussions with a number of other retailers andhopes to make further distribution announcements in 2006. In addition to the onelitre packs, the Company is also developing a 250ml bottle of Sirco(TM) fordistribution to retailers in mid 2006. This bottle will have an extended shelflife and is intended to widen the distribution base to include independentchemists, convenience stores and food service industry channels such as health,education and travel outlets. Sirco(TM) is the first heart health product to contain the patentedFruitflow(TM) technology. Fruitflow(TM) was developed by Provexis in order tohelp regular "healthy" consumers reduce the risk of heart attack and stroke. Thenatural bioactive works by reducing blood platelet aggregation ("thinning theblood"), a significant contributing factor to a thrombosis (internal bloodclot). Sirco(TM) carries the health claim "Helps to Maintain a Healthy Heart andBenefits Circulation" and is approved by the leading heart health charity, HEARTUK. Commenting on the forthcoming launch Dr Stephen Franklin, CEO of Provexis, said: "This marks a significant milestone for Provexis and we are delighted that wehave secured distribution with two of the largest UK supermarkets. Bothretailers are ideal outlets in terms of the demographics and target market forthis product. We will be investing in media advertising as well as in-storeactivity to ensure we maximise this substantial opportunity. We look forward to growing the retailer base for Sirco(TM) throughout 2006,whilst in parallel securing licensing arrangements with major international foodpartners to integrate the FruitFlow(TM) technology into new food products inglobal markets." For further information please contact: Provexis plcDr Stephen Franklin 020 8392 6631 Bell Pottinger Corporate & FinancialAnn-Marie Wilkinson/Emma Kent 020 7861 3232 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Jan 202112:37 pmRNSHalf-year Report
31st Dec 20201:00 pmRNSTotal Voting Rights
17th Dec 20207:00 amRNS£1m placing & update re HY results
16th Nov 20207:00 amRNSExclusive Distribution Agreement for Chinese CBEC
30th Oct 20202:09 pmRNSResult of AGM
30th Sep 20207:00 amRNSFinal Results
28th Aug 20205:00 pmRNSTotal Voting Rights
13th Aug 20207:00 amRNSFruitflow® & Blood Pressure - purchase of IP
7th Aug 20205:11 pmRNSHolding(s) in Company
27th May 20207:00 amRNSHolding(s) in Company
31st Dec 20197:13 amRNSInterim Results and Total Voting Rights
11th Dec 20197:00 amRNSPlacing of new ordinary shares to raise £0.301m
4th Oct 20191:19 pmRNSResult of AGM
12th Sep 20193:19 pmRNSDirector/PDMR Shareholding
11th Sep 20194:02 pmRNSGrant of Share Options
10th Sep 20197:00 amRNSFinal Results
2nd Aug 20197:00 amRNSCollaboration agreement with By-Health Co., Ltd.
31st Jul 20197:00 amRNSTrading Update
27th Jun 20193:11 pmRNSTiming of trading update
12th Apr 20197:00 amRNSBoard changes
8th Mar 20199:44 amRNSHolding(s) in Company
31st Dec 20187:00 amRNSHalf-year Report
1st Nov 20181:00 pmRNSChange of Adviser and AIM Rule 17 notice
25th Oct 20181:55 pmRNSResult of AGM
16th Oct 20187:00 amRNSHolding(s) in Company
9th Oct 20184:25 pmRNSHolding(s) in Company
27th Sep 20187:10 amRNSFinal Results
27th Sep 20187:00 amRNSResults of Placing
4th Jul 20187:00 amRNSDirectorate Change - Frédéric Boned
25th Jun 20187:00 amRNSFruitflow®+ Omega-3 launch in Holland & Barrett
5th Feb 20182:16 pmRNSHolding(s) in Company
31st Jan 20188:21 amRNSDirectorate Change - Krijn Rietveld
2nd Jan 20187:00 amRNSGrant of Share Options
29th Dec 20177:09 amRNSHalf-year Report
4th Dec 20177:00 amRNSPatent application - Fruitflow and air pollution
10th Nov 20174:40 pmRNSSecond Price Monitoring Extn
10th Nov 20174:35 pmRNSPrice Monitoring Extension
2nd Nov 20174:41 pmRNSSecond Price Monitoring Extn
2nd Nov 20174:35 pmRNSPrice Monitoring Extension
31st Oct 20174:40 pmRNSSecond Price Monitoring Extn
31st Oct 20174:35 pmRNSPrice Monitoring Extension
3rd Oct 20174:10 pmRNSResult of AGM
26th Sep 20172:44 pmRNSStudy Publication
7th Sep 20177:00 amRNSPreliminary Results
4th Aug 20178:00 amRNSHolding(s) in Company
31st Jul 20177:59 amRNSResults of placing
28th Jul 20174:30 pmRNSFunding Update
3rd Jul 20177:00 amRNSFunding Update
9th Jun 20174:35 pmRNSPrice Monitoring Extension
5th Jun 20174:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.